Webinar Date/Time: Thu, Mar 2, 2023 1:00 PM EST
Improve patient engagement and retention for genomics-based clinical trials. Learn how a well-planned genetic screening program can lead to successful patient screening and recruitment.
Register Free: https://www.pharmtech.com/pt/genomics
Event Overview:
Genomics-based clinical trials often target a very small subset of a patient population, which makes finding and recruiting patients extremely challenging. Implementing effective engagement and retention strategies are critical. A well-planned genetic screening program can be a key difference between trial success and failure.
Kelly Athman, M.S., CGC, Sr. Director of Medical Affairs at InformedDNA—the leading applied genomics solutions provider for pharmaceutical and biotech companies conducting clinical trials in the U.S.—will share strategies to maximize genomics-based clinical trial success.
Key Learning Objectives:
Who Should Attend:
Speaker
Kelly Athman, MS, CGC
Senior Director, Medical Affairs
InformedDNA
Kelly Athman, MS, CGC is a board-certified genetic counselor with more than 15 years of experience in the healthcare industry. Passionate about increasing patient access to high-quality genomics care drives her as the senior director of medical affairs at InformedDNA. Having worked directly with patients and families who experience the impact of having limited therapeutic options for rare genetic conditions fuels her work and enables Kelly to bring a unique clinical perspective on the promise of genomics-based treatments. Prior to joining InformedDNA, she served as a genetic counselor for Fairview Hospitals and Clinics, Children’s Mercy Hospital, and CentraCare Health Systems. Kelly holds an M.S. in Molecular, Cellular, Developmental Biology & Genetics and a B.A. in Psychology and Biology from the University of Minnesota
Register Free: https://www.pharmtech.com/pt/genomics
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.